1439 related articles for article (PubMed ID: 31385163)
1. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
3. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
[TBL] [Abstract][Full Text] [Related]
5. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
6. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia.
Carbone A; Bottino R; Attena E; Parisi V; Conte M; D'Andrea A; Imbalzano E; Golino P; Russo V
J Thromb Thrombolysis; 2023 Feb; 55(2):222-227. PubMed ID: 36472719
[TBL] [Abstract][Full Text] [Related]
8. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
10. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
[TBL] [Abstract][Full Text] [Related]
11. Atrial Fibrillation and Mitral Regurgitation: Clinical Performance of Direct Oral Anticoagulants in a Real-World Setting.
Melillo E; Rago A; Proietti R; Attena E; Carrella M; Golino P; D'Onofrio A; Nigro G; Russo V
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):564-569. PubMed ID: 32602356
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulants' Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study.
Frappé P; Cogneau J; Gaboreau Y; Abenhaïm N; Bayen M; Guichard C; Jacquet JP; Lacoin F; Liébart S; Bertoletti L; Bosson JL;
Ann Fam Med; 2020 Mar; 18(2):131-138. PubMed ID: 32152017
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
15. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
17. Incidence of thromboembolic events following atrial fibrillation catheter ablation and rate control strategies according to the kind of oral anticoagulation: A systematic review and meta-analysis.
Toso E; Peyracchia M; Matta M; D'Ascenzo F; Gaita F; Kornej J; Hindricks G; Jared Bunch T; Saliba W
Int J Cardiol; 2018 Nov; 270():172-179. PubMed ID: 29945808
[TBL] [Abstract][Full Text] [Related]
18. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
[TBL] [Abstract][Full Text] [Related]
19. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.
Lee SR; Choi EK; Park CS; Han KD; Jung JH; Oh S; Lip GYH
J Am Coll Cardiol; 2019 Mar; 73(8):919-931. PubMed ID: 30819360
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study.
Admassie E; Chalmers L; Bereznicki LR
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):329-336. PubMed ID: 29642709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
